Identification of Cytochrome P450 Enzymes Involved in the Metabolism of FK228, a Potent Histone Deacetylase Inhibitor, in Human Liver Microsomes
- 1 January 2005
- journal article
- Published by Pharmaceutical Society of Japan in Biological & Pharmaceutical Bulletin
- Vol. 28 (1), 124-129
- https://doi.org/10.1248/bpb.28.124
Abstract
FK228 (FR901228, depsipeptide) is a potent histone deacetylase inhibitor currently in phase II clinical trials for cancer treatment. In the present study, the cytochrome P450 (P450) enzymes responsible for FK228 metabolism in human liver microsomes were investigated. Incubation with human liver microsomes in the presence of an NADPH-generating system revealed that FK228 is metabolized to at least 10 different metabolites. Km and Vmax values for FK228 disappearance were 20.3 μM and 561.9 pmol/min/mg protein, respectively. Further studies were performed at a substrate concentration of 10 μM (half the Km value for FK228 disappearance). FK228 disappearance activities in human liver microsomes from 12 individuals strongly correlated (r2=0.957) with testosterone 6β-hydroxylase activities, a marker enzyme activity of CYP3A4/5, but not with other P450 enzyme-specific activities (CYP1A2, 2A6, 2C8, 2C9, 2C19, 2D6, and 4A). Among 14 recombinant heterologously expressed human P450s examined, CYP3A4 exhibited the highest activity of FK228 disappearance. CYP3A5, 1A1, 2B6, and 2C19 showed 16.8%, 5.2%, 1.6%, and 1.3% of the activity of CYP3A4, respectively. Other P450s showed no significant metabolic activity toward FK228. In addition, FK228 disappearance in human liver microsomes was markedly inhibited by ketoconazole, a potent CYP3A4 inhibitor, and an anti-CYP3A4 antibody. These results indicate that the metabolism of FK228 in human liver microsomes is catalyzed mainly by CYP3A enzymes, particularly CYP3A4.Keywords
This publication has 17 references indexed in Scilit:
- Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the bloodRapid Communications in Mass Spectrometry, 2003
- Summary of information on human CYP enzymes: human P450 metabolism dataDrug Metabolism Reviews, 2002
- Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450Xenobiotica, 2000
- FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase InhibitorExperimental Cell Research, 1998
- IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3AAnnual Review of Pharmacology and Toxicology, 1998
- Molecular genetics of the human cytochrome P450 monooxygenase superfamilyXenobiotica, 1998
- Procarcinogen activation by cytochrome P450 3A4 and 3A5 expressed in Escherichia coli and by human liver microsomesCarcinogenesis: Integrative Cancer Research, 1995
- Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9Xenobiotica, 1995
- FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity.The Journal of Antibiotics, 1994
- A pharmacokinetic analysis program (multi) for microcomputer.Journal of Pharmacobio-Dynamics, 1981